pre-IPO PHARMA

COMPANY OVERVIEW

Bantam Pharmaceutical is a drug discovery and development company channeling the power of mitochondrial dynamics to address unmet needs in oncology. Using its unique expertise in mitochondrial cellular biology, Bantam is developing novel, first-in-class small molecule oral therapeutics for difficult-to-treat hematological and solid tumors. Bantam is currently pursuing an IND application for its lead candidate, BTM-3566, in B-cell malignancies.


LOCATION


THERAPEUTIC AREAS


WEBSITE

https://bantampharma.com/


CAREER WEBSITE

None


SOCIAL MEDIA


INVESTORS


PRESS RELEASES


Jan 9, 2023

BANTAM PHARMACEUTICAL TO PRESENT AT BIOTECH SHOWCASE™ 2023


Jun 23, 2022

Bantam Pharmaceutical and Collaborators to Present New Data in Support of its Clinical Candidate BTM-3566 at Third AACR International Meeting - Advances in Malignant Lymphoma


Apr 8, 2022

Bantam Pharmaceutical and Collaborators to Present New Data in Support of its lead drug BTM-3566 at AACR Annual Meeting 2022


Dec 13, 2021

Data on Bantam Pharmaceutical's Lead Drug, BTM-3566 Highlighted During Oral Session on Targeting Mitochondria Pathways in Lymphoid Cancers at the 63rd Annual Meeting of the American Society of Hematology


Nov 18, 2021

Bantam Pharmaceutical Announces Data on its lead drug, BTM-3566 to be Presented at the 63rd Annual Meeting of the American Society of Hematology


For More Press Releases


Google Analytics Alternative